NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
9.82
+0.19 (1.97%)
At close: Nov 6, 2025, 4:00 PM EST
9.82
0.00 (0.00%)
After-hours: Nov 6, 2025, 4:10 PM EST
NextCure Employees
NextCure had 43 employees as of December 31, 2024. The number of employees decreased by 39 or -47.56% compared to the previous year.
Employees
43
Change (1Y)
-39
Growth (1Y)
-47.56%
Revenue / Employee
n/a
Profits / Employee
-$1,349,093
Market Cap
26.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | -39 | -47.56% |
| Dec 31, 2023 | 82 | -17 | -17.17% |
| Dec 31, 2022 | 99 | 12 | 13.79% |
| Dec 31, 2021 | 87 | -3 | -3.33% |
| Dec 31, 2020 | 90 | 21 | 30.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NXTC News
- 1 day ago - NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 21 days ago - NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - GlobeNewsWire
- 2 months ago - NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta - GlobeNewsWire
- 5 months ago - NextCure signs up to $745 million deal with China's Simcere to develop cancer drug - Reuters
- 5 months ago - NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - GlobeNewsWire
- 5 months ago - NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - GlobeNewsWire